tiprankstipranks
Clorox Company (CLX)
NYSE:CLX
Want to see CLX full AI Analyst Report?

Clorox (CLX) AI Stock Analysis

3,177 Followers

Top Page

CLX

Clorox

(NYSE:CLX)

Select Model
Select Model
Select Model
Neutral 56 (OpenAI - 5.2)
Rating:56Neutral
Price Target:
$100.00
▼(-4.38% Downside)
Action:Reiterated
Date:05/29/26
CLX scores in the mid-range primarily due to elevated financial risk (negative equity, high leverage, and weakening recent cash-flow trends) despite improved TTM profitability. The earnings outlook is mixed with notable near-term margin and cost headwinds, while valuation is supported by a moderate P/E and a high dividend yield; technicals remain weaker on a longer-term trend basis.
Positive Factors
Brand Strength & Innovation
Durable brand and innovation momentum (Clorox PURE, Scentiva, other cleaning launches) supports repeat purchase, shelf presence and premium positioning. Sustained new-product velocity and regained distribution reduce private-label vulnerability and underpin mid-term revenue and margin recovery.
Negative Factors
Weak Balance Sheet / Negative Equity
Negative trailing equity and elevated debt constrain financial flexibility and raise refinancing and covenant risk. This weaker capital structure limits the firm's ability to invest, pursue opportunistic M&A, or absorb shocks, increasing exposure to interest-cost and macro swings over coming quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
Brand Strength & Innovation
Durable brand and innovation momentum (Clorox PURE, Scentiva, other cleaning launches) supports repeat purchase, shelf presence and premium positioning. Sustained new-product velocity and regained distribution reduce private-label vulnerability and underpin mid-term revenue and margin recovery.
Read all positive factors

Clorox Key Performance Indicators (KPIs)

Any
Any
Revenue by Segment
Revenue by Segment
Highlights income from different business units, showing which areas drive growth and profitability, and where the company might focus future investments.
Chart InsightsHousehold is the clearest weak spot — negative pricing and volume have driven recent troughs and explain volatile quarter-to-quarter swings, while Health & Wellness and Lifestyle look steadier and are the primary levers for near-term recovery. Recent ERP prebuilds created a one‑quarter shipment boost that will reverse, adding near‑term volatility, but ERP completion should improve RGM/pack decisions, deliver ~3.5 points of normalized shipments and a material FY27 EPS tailwind; margin rebound depends on the back‑half innovation ramp and reduced logistics/ERP drag.
Data provided by:The Fly

Clorox (CLX) vs. SPDR S&P 500 ETF (SPY)

Clorox Business Overview & Revenue Model

Company Description
The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, su...
How the Company Makes Money
Clorox primarily makes money by manufacturing and selling branded consumer and professional products to retailers, distributors, and other channel partners, recognizing revenue from product sales (net of trade promotions, discounts, and allowances...

Clorox Earnings Call Summary

Earnings Call Date:Apr 30, 2026
(Q3-2026)
|
% Change Since: |
Next Earnings Date:Aug 05, 2026
Earnings Call Sentiment Neutral
The call was mixed: management highlighted important strategic and operational progress (ERP completion, strong innovation, distribution gains, Glad and Hidden Valley improvements, and the accretive GOJO acquisition with targeted synergies) but also disclosed significant near-term margin headwinds (higher logistics/input costs, one-time acquisition and cost-acceleration charges), category weakness in Food, and a bumpy conversion in Litter. The tone was cautiously optimistic — confident in long-term plans and tools to mitigate inflation and drive value superiority, while acknowledging material short-term pressure and uncertainty.
Positive Updates
ERP Implementation Completed and Stabilization
The multi-phase ERP implementation was completed in Q3; service levels have stabilized and related incremental costs have come down. Management stated minimal incremental ERP-related costs by the end of Q3 and expects little to no incremental ERP cost in Q4, improving the foundation for execution and margin recovery.
Negative Updates
Q3 Results Missed Expectations; Mixed Performance
Company said Q3 results were mixed and fell short of expectations. Management called out a few businesses that showed slower improvement than planned and said overall Q3 performance was below internal expectations.
Read all updates
Q3-2026 Updates
Negative
ERP Implementation Completed and Stabilization
The multi-phase ERP implementation was completed in Q3; service levels have stabilized and related incremental costs have come down. Management stated minimal incremental ERP-related costs by the end of Q3 and expects little to no incremental ERP cost in Q4, improving the foundation for execution and margin recovery.
Read all positive updates
Company Guidance
Management reiterated that fiscal 2026 remains uncertain but gave several quantified assumptions: they’re modeling roughly $100/barrel oil in Q4, which they estimate will be a $20–25M Q4 headwind (~130 bps of gross margin); Q4 gross margin is running about 5 percentage points below last year (~150 bps from lapping ERP-related operating leverage, ~200 bps tied to the GOJO acquisition — including a non‑recurring ~150‑bps inventory step‑up — and another ~100–150 bps from elevated input costs); GOJO adds an ~$800M business (≈$200M in Q4, ~+10% to the quarter and ~+3% to the year), is expected to be EBITDA‑neutral in year 1 with at least $50M of run‑rate synergies targeted, ~50 bps of gross‑margin dilution in year 1, <1 point SG&A dilution and an initial ~1‑point reduction in A&P as a percent of sales (≈‑25 bps full year); interest expense rises ~+$30M in Q4 and ~+$110M in the following year above a ~$100M pre‑acquisition run rate; operationally Q3 total distribution points were +5%, company categories are expected roughly 0–1% for the remainder of the year (litter mid‑single digits, food down mid‑single digits), ERP implementation is complete with ERP‑related logistics/fulfillment costs largely abating in Q4, and there is a one‑time ~50‑bps gross‑margin headwind to accelerate structural cost savings into FY27.

Clorox Financial Statement Overview

Summary
Income statement strength (improved TTM profitability with ~11.2% net margin and ~12.0% EBIT margin) is offset by major balance-sheet risk (TTM equity slightly negative and elevated debt versus assets) and weakening cash-flow momentum (TTM free cash flow down sharply and softer cash conversion).
Income Statement
72
Positive
Balance Sheet
28
Negative
Cash Flow
54
Neutral
BreakdownTTMJun 2025Jun 2024Jun 2023Jun 2022Jun 2021
Income Statement
Total Revenue6.76B7.10B7.09B7.39B7.11B7.34B
Gross Profit2.96B3.21B3.05B2.91B2.54B3.20B
EBITDA1.31B1.39B723.00M564.00M937.00M1.21B
Net Income756.00M810.00M280.00M149.00M462.00M710.00M
Balance Sheet
Total Assets6.44B5.56B5.75B5.95B6.16B6.33B
Cash, Cash Equivalents and Short-Term Investments1.19B167.00M202.00M367.00M183.00M319.00M
Total Debt4.49B2.88B2.90B2.92B3.10B3.17B
Total Liabilities6.34B5.08B5.26B5.56B5.43B5.74B
Stockholders Equity-67.00M321.00M328.00M220.00M556.00M411.00M
Cash Flow
Free Cash Flow380.00M761.00M483.00M930.00M535.00M945.00M
Operating Cash Flow576.00M981.00M695.00M1.16B786.00M1.28B
Investing Cash Flow-196.00M-94.00M-175.00M-223.00M-229.00M-452.00M
Financing Cash Flow578.00M-924.00M-655.00M-753.00M-689.00M-1.39B

Clorox Technical Analysis

Technical Analysis Sentiment
Negative
Last Price104.58
Price Trends
50DMA
96.47
Negative
100DMA
105.26
Negative
200DMA
107.26
Negative
Market Momentum
MACD
-1.55
Positive
RSI
37.84
Neutral
STOCH
11.02
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CLX, the sentiment is Negative. The current price of 104.58 is above the 20-day moving average (MA) of 92.13, above the 50-day MA of 96.47, and below the 200-day MA of 107.26, indicating a bearish trend. The MACD of -1.55 indicates Positive momentum. The RSI at 37.84 is Neutral, neither overbought nor oversold. The STOCH value of 11.02 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CLX.

Clorox Risk Analysis

Clorox disclosed 26 risk factors in its most recent earnings report. Clorox reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Clorox Peers Comparison

Overall Rating
UnderperformOutperform
Sector (62)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
76
Outperform
$327.91B20.3731.28%2.92%3.33%8.06%
65
Neutral
$22.78B29.9717.45%1.38%2.22%29.40%
64
Neutral
$70.63B32.63475.13%2.67%4.26%-27.12%
62
Neutral
$20.33B14.63-3.31%3.23%1.93%-12.26%
61
Neutral
$32.36B14.84143.64%5.03%-16.17%-13.40%
56
Neutral
$10.84B14.212826.17%5.05%-3.69%10.26%
54
Neutral
$30.18B-120.00-6.29%1.30%0.71%71.47%
* Consumer Defensive Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
CLX
Clorox
88.53
-33.28
-27.32%
CHD
Church & Dwight
92.89
-4.82
-4.93%
CL
Colgate-Palmolive
84.87
-3.06
-3.48%
EL
The Estée Lauder Companies
82.05
15.58
23.43%
KMB
Kimberly Clark
94.76
-34.78
-26.85%
PG
Procter & Gamble
140.19
-18.06
-11.41%

Clorox Corporate Events

Business Operations and StrategyExecutive/Board Changes
Clorox Initiates CEO Succession Following Linda Rendle’s Exit
Negative
May 28, 2026
The Clorox Company announced on May 28, 2026, that Chair and CEO Linda Rendle has asked the board to begin a comprehensive search for a new chief executive as she plans to step down for health reasons. Rendle, who has led Clorox for six years and ...
Private Placements and Financing
Clorox Raises $1.5 Billion Through Senior Notes Offering
Positive
May 11, 2026
On May 6, 2026, The Clorox Company executed an underwriting agreement to issue $1.5 billion in senior notes across 4.700% notes due 2031, 4.950% notes due 2033, and 5.250% notes due 2036 in an underwritten registered public offering. The transacti...
Business Operations and StrategyFinancial DisclosuresM&A Transactions
Clorox Posts Mixed Q3 Results, Lowers Fiscal 2026 Outlook
Negative
Apr 30, 2026
On April 30, 2026, Clorox reported mixed results for its third quarter ended March 31, 2026, with net sales flat at $1.67 billion and organic sales down 1% versus a year earlier, while gross margin compressed by 140 basis points to 43.2% on higher...
Business Operations and StrategyM&A Transactions
Clorox Completes Acquisition of Purell Maker GOJO Industries
Positive
Apr 1, 2026
On April 1, 2026, Clorox completed its previously announced acquisition of GOJO Industries, the maker of Purell, bringing the well-known sanitizing brand and GOJO&#8217;s broader health and hygiene solutions under the Clorox umbrella. The deal, st...
Business Operations and StrategyM&A TransactionsPrivate Placements and Financing
Clorox Secures New Credit Facilities for GOJO Acquisition
Positive
Mar 11, 2026
On March 6, 2026, Clorox arranged two new senior unsecured credit facilities totaling up to $2.25 billion in connection with its planned purchase of all membership interests in GOJO Industries, maker of PURELL. The company secured a $1 billion 364...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: May 29, 2026